Table 1.
Patient demographics and clinical characteristics prior to combination treatment.
| Parameter | N = 148 |
|---|---|
| Age at study index (years), mean (SD) | 46.9 (11.5) |
| Female, n (%) | 138 (93.2) |
| Time since migraine diagnosis (years), mean (SD) | 3.1 (2.1) |
| Time since onabotulinumtoxinA treatment initiation (years), mean (SD) | 2.6 (2.0) |
| Time since most recent (pre-index) onabotulinumtoxinA injection (weeks) | 5.0 (4.8) |
| Index mAb treatment (mg), n (%) | |
| Erenumab (Aimovig), 140 mg | 34 (23.0) |
| Erenumab (Aimovig), 70 mg | 50 (33.8) |
| Fremanezumab (Ajovy), 225 mg | 63 (42.6) |
| Galcanezumab (Emgality), 120 mga | 1 (0.7) |
| Baseline concomitant medication use, n (%) | 143 (96.6) |
| Acute (top 3), n (%) | |
| Sumatriptan | 41 (27.7) |
| Naproxen | 27 (18.2) |
| Naratriptan | 21 (14.2) |
| Preventive (top 3), n (%) | |
| Amitriptyline | 25 (16.9) |
| Gabapentin | 21 (14.2) |
| Topiramate | 17 (11.5) |
| Comorbid conditions (any), n (%) | 142 (95.9) |
mg, milligram; n, number; SD, standard deviation.
aGalcanezumab is administered as a 240 mg loading dose, followed by monthly doses of 120 mg.